Related Experiment Video
Updated: Mar 26, 2026
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels
Rolf Ljung1, Kathelijn Fischer, Manuel Carcao
1Rolf Ljung, MD, Department of Pediatrics, Lund University, Skåne University Hospital, Ing 108, plan 2, 205 02 Malmö, Sweden, Tel.: +46 40331000, Fax: +46 40336226,
Insights
Optimizing hemophilia A treatment involves choosing between fixed or individualized factor VIII prophylaxis. Tailoring regimens to patient factors and ensuring adherence are crucial for preventing bleeds and improving quality of life.
Area of Science:
- Hematology
- Pediatric Hematology
- Pharmacoeconomics
Background:
- Hemophilia A therapy is guided by disease severity, reflected in factor VIII activity levels.
- Continuous factor replacement prophylaxis is the standard of care for severe hemophilia A, especially in children.
- Developing countries are increasingly adopting this standard of care.
Purpose of the Study:
- To determine the optimal prophylaxis regimen for hemophilia A.
- To balance bleeding prevention, arthropathy, quality of life, and cost-effectiveness.
- To explore individualized versus fixed prophylaxis strategies.
Main Methods:
- Review of current prophylaxis practices and guidelines for hemophilia A.
- Analysis of factors influencing prophylaxis regimen selection.
- Consideration of patient-specific and product-specific variables.
Main Results:
- Prophylaxis regimens should aim to prevent bleeding events and arthropathy.
- Individualized prophylaxis considers patient factors (bleeding phenotype, activity, age, joint status) and product factors (factor half-life).
- Adherence to therapy is paramount for optimizing outcomes regardless of the chosen regimen.
Conclusions:
- The choice between fixed and individualized prophylaxis for hemophilia A requires careful consideration of multiple factors.
- Tailoring treatment to individual patient needs and ensuring therapy adherence are key to effective management.
- Future research may further refine individualized prophylaxis strategies for hemophilia A.
Abstract:
Current therapy for haemophilia A is guided by severity of the disease, which in turn is best reflected in patients' endogenous factor VIII activity levels. For patients with severe haemophilia (particularly children), prophylaxis with continuous routine factor replacement has become standard of care in developed countries and is gradually becoming the standard of care in developing countries. The question arises then: what is an appropriate prophylaxis regimen to prevent bleeding events and arthropathy, while also maximizing patient quality of life and taking into consideration the costs of prophylaxis? Should all patients be treated with one standard, fixed prophylaxis regimen, or should prophylaxis be individualised for each patient? If so, what factors need to be considered in choosing the appropriate dose and frequency of factor administration? If prophylaxis is tailored to the individual patient, then patient-related factors (bleeding phenotype, activity profiles, age, joint status) and product-specific factors (half-life of the replacement factor in the individual patient) will determine the choice of regimen, whether it be a fixed-regimen prophylaxis or prophylaxis that is tailored to patient activity and bleeding risk. Regardless of the choice of prophylaxis regimen, for any regimen to be effective, adherence to therapy is key to optimising outcomes.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:29Therapeutic Drug Monitoring: Affecting Factors
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview